Related Experiment Video

Updated: Mar 28, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

Epidermal growth factor receptor-targeted therapy in colorectal cancer

WeiDong Xu1, HuaYong Jing2, FuLi Zhang2

  • 1Department of Radiation Oncology,The Military General Hospital of Beijing PLA,No.5 Nanmencang, Dongcheng, Beijing,100700, China, xwddc@21cn.com.

Frontiers in Bioscience (Landmark Edition)
|December 29, 2015
PubMed

Insights

Epidermal growth factor receptor (EGFR) targeted therapies, including cetuximab and panitumumab, are crucial for advanced colorectal cancer (CRC). This review details their efficacy and mechanisms in CRC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) signaling is integral to colorectal cancer (CRC) development and progression.
  • EGFR expression levels are linked to patient prognosis in CRC.
  • EGFR-targeted therapies are established treatments for advanced CRC.

Purpose of the Study:

  • To review current EGFR-targeted therapies for colorectal cancer.
  • To focus on the efficacy and mechanisms of cetuximab and panitumumab in CRC treatment.

Main Methods:

  • Literature review of clinical trials and in vivo studies.
  • Analysis of EGFR antibody efficacy and mechanisms in CRC.

Main Results:

  • Cetuximab and panitumumab are key EGFR antibodies used in CRC treatment.
  • Ongoing research investigates their precise mechanisms and clinical effectiveness.

Conclusions:

  • EGFR-targeted antibodies represent a significant therapeutic strategy for colorectal cancer.
  • Further research is essential to optimize their use and understand their action.

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68